Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy

Blood

Volumn 115, Issue 17, 2010, Pages 3580-3588

  Li, Jia ^a   Sze, Daniel M Y ^a,b,c   Brown, Ross D ^b   Cowley, Mark J ^d   Kaplan, Warren ^d,e   Mo, Sui Lin ^a,f   Yang, Shihong ^b   Aklilu, Esther ^b   Kabani, Karieshma ^b   Loh, Yen S ^a   Yamagishi, Tetsuo ^a   Chen, Yuling ^a,e   Ho, P Joy ^b   Joshua, Douglas E ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NUCLEOSIDE ANALOG; T CELL RECEPTOR VBETA; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL CLONING; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL EXPANSION; CLINICAL ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA MICROARRAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 77951740292     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-246991     Document Type: Article

References (50)

1. Fujii S. Role of interferon-alpha and clonally expanded T cells in the immunotherapy of chronic myelogenous leukemia. Leuk Lymphoma. 2000;38(1-2):21-38. (Pubitemid 30224320)
2. Li YQ, Yang LJ, Chen SH, et al. T cell receptor Vbeta repertoire usage and clonal expansion of T cells in chronic myelogenous leukemia. Chin Med J. 2004;117(6):840-843.
3. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8):1398-1405.
4. Epling-Burnette PK, Painter JS, Rollison DE, et al. Prevalence and clinical association of clonal T cell expansions in myelodysplastic syndrome. Leukemia. 2007;21(4):659-667.
5. de Vries AC, Langerak AW, Verhaaf B, et al. T cell receptor Vbeta CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDSRC) and severe aplastic anaemia. Leukemia. 2008;22(6):1170-1174. (Pubitemid 351833784)
6. Brown RD, Yuen E, Nelson M, et al. The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia. 1997;11(8):1312-1317. (Pubitemid 27387309)
7. Raitakari M, Brown RD, Sze D, et al. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br J Haematol. 2000;110(1):203-209. (Pubitemid 30625609)
8. Sze DM-Y, Giesajtis G, Brown RD, et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28+ compartment. Blood. 2001;98(9):2817-2827.
9. Raitakari M, Brown RD, Gibson J, et al. T cells in myeloma. Hematol Oncol. 2003;21(1):33-42.
10. Sze DM-Y, Brown RD, Yuen E, et al. Clonal cytotoxic T cells in myeloma. Leuk Lymphoma. 2003;44(10):1667-1674.
11. Brown RD, Murray A, Sze DM, et al. The immunomodulatory action of thalidomide in patients with multiple myeloma involves a clonal expansion of late-differentiated cytotoxic effector cells [abstract]. Blood. 2005;106(11):359b. Abstract 5108.
12. Lim SH, Badros A, Lue C, et al. Distinct T cell clonal expansion in the vicinity of tumor cells in plasmacytoma. Cancer. 2001;91(5):900-908. (Pubitemid 32198602)
13. Orsini E, Alvea EP, Schlossman R, et al. Changes in T cell receptor repertoire associated with graftversus-host disease in patients with relapsed multiple myeloma after donor lyphocyte infusion. Bone Marrow Transplant. 2000;25(6):623-632. (Pubitemid 30156587)
14. Halapi E, Werner A, Wahlström J, et al. T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumour burden. Eur J Immunol. 1997;27(9):2245-2252. (Pubitemid 27404307)
15. Kay N, Leong T, Kyle RA, et al. Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a study of the Eastern Cooperative Oncology Group (E9487). Leuk Lymphoma. 1999;33(1-2):127-133. (Pubitemid 29116402)
16. Brown RD, Spencer A, Ho PJ, et al. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leuk Lymphoma. 2009;50(11):1860-1864.
17. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/ acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27(2):250-255.
18. Leleu X, Tamburini J, Roccaoro A, et al. Balancing risk versus benefit in the treatment of Waldenström's macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma. 2009;9(1):71-73.
19. Assaf C, Hummel M, Steinhoff M, et al. Early TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications. Blood. 2005;105(2):503-510. (Pubitemid 40070728)
20. Labrecque N, McGrath HSubramanyam M, et al. Human T cells respond to mouse mammary tumor virus-encoded superantigen: V beta restriction and conserved evolutionary features. J Exp Med. 1993;177(6):1735-1743. (Pubitemid 23146140)
21. Choi YW, Kotzin B, Herron L, et al. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci U S A. 1989;86(22):8941-8945.
22. Yousfi Monod M, Giudicelli V, Chaume D, et al. IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinformatics. 2004;20(suppl 1):i379-i385. (Pubitemid 41296713)
23. Gautier L, Cope L, Bolstad BM, et al. Affy: analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307-315. (Pubitemid 38262761)
24. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5(3):299-314.
25. Gentleman RC, Carey VJ, Bates DJ, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.1-R80.16.
26. Subramanina A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;(43)102:15545-15550. (Pubitemid 41528093)
27. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34(2):374-378. (Pubitemid 36184095)
28. National Center for Biotechnology Information. Gene Expression Omnibus (GEO). http://www.ncbi.nlm.nih.gov/geo. Accessed May 12, 2009.
29. Lazuardi L, Herndler-Brandstetter D, Brunner S, et al. Microarray analysis reveals similarity between CD8+CD28- T cells from young and elderly persons, but not of CD8+CD28+ T cells. Biogerontology. 2009;10(2):191-202.
30. Rosenkilde MM, Benned-Jensen T, Andersen H, et al. Molecular pharmacological phenotyping of EBI2: an orphan seven-transmembrane receptor with constitutive activity. J Biol Chem. 2006;281(19):13199-13208. (Pubitemid 43855231)
31. Yamanaka R, Arao T, Yajima N, et al. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene. 2006;25(44):5994-6002. (Pubitemid 44477293)
32. Araki Y, Fann M, Wersto R, et al. Histone acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: perforin and granzyme B). J Immunol. 2008;180(12):8102-8108.
33. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, eds. Bioinformatics and Computational Biology Solutions using R and Bioconductor. New York, NY: Springer; 2005:397-420.
34. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article 3.
35. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003;100(16):9440-9445.
36. Fiebig AA, Zhu W, Hollerbach C, et al. Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer. 2006;6:213-227.
37. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401(6748):86-90. (Pubitemid 29418448)
38. Makino K, Day CP, Wang SC, et al. Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-kappaB antiapoptotic pathway. Oncogene. 2004;23(21):3883-3887. (Pubitemid 38725701)
39. Kawabuchi M, Satomi Y, Takao T, et al. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature. 2000;404(6781):999-1003. (Pubitemid 30243594)
40. Takeuchi S, Takayama Y, Ogawa A, et al. Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk. J Biol Chem. 2000;275(38):29183-29186. (Pubitemid 32043785)
41. Tzachanis D, Freeman GJ, Hirano N, et al. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol. 2001;2(12):1174-1182. (Pubitemid 33130153)
42. Tzachanis D, Boussiotis VA. Tob, a member of the APRO family, regulates immunological quiescence and tumor suppression. Cell Cycle. 2009;8(7):1019-1025.
43. Bouchard C, Thieke K, Maier A, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999;18(19):5321-5333. (Pubitemid 29465582)
44. Yamato K, Koseki T, Ohguchi M, et al. Activin A induction of cell-cycle arrest involves modulation of Cyclin D2 and p21CIP1/WAF1 in plasmacytic cells. Mol Endocrinol. 1997;11(8):1044-1052. (Pubitemid 27278827)
45. Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol. 1999;19(7):4672-4683.
46. Baughn LB, Liberto MD, Wu KD, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclindependent kinase 4/6. Cancer Res. 2006;66(15):7661-7667.
47. Nika K, Hyunh H, Williams S, et al. Haematopoietic protein tyrosine phosphatase (HePTP) phosphorylation by cAMP-dependent protein kinase in T-cells: dynamics and subcellular location. Biochem J. 2004;378(pt 2):335-342. (Pubitemid 38367224)
48. Saxena M, Williams S, Gilman J, et al. Negative regulation of T cell antigen receptor signal transduction by hematopoietic tyrosine phosphatase (HePTP). J Biol Chem. 1998;273(25):15340-15344. (Pubitemid 28298136)
49. Cong F, Goff SP. c-Abl-induced apoptosis, but not cell cycle arrest, requires mitogen-activated protein kinase kinase 6 activation. Proc Natl Acad Sci U S A. 1999;96(24):13819-13824.
50. Imaki H, Nakayama K, Delehouzee S, et al. Cell cycle-dependent regulation of the Skp2 promoter by GA-binding protein. Cancer Res. 2003;63(15):4607-4613. (Pubitemid 36951037)